DelveInsight has launched a new report on “Astrocytoma – Market Insights, Epidemiology, and Market Forecast-2030”.
DelveInsight’s “Astrocytoma – Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Astrocytoma, historical and forecasted epidemiology as well as the Astrocytoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some of the key facts of the Astrocytoma Market Report:
-
According to Hertz et al., 2020, a study aimed to compare the worldwide incidence rates of CNS cancers between 1990 and 2016 showed a 17.3% increase worldwide, reaching 32.5% for Western Europe. Furthermore, from a cohort of 264,241 pediatric and adult patients affected by various CNS tumors between 2003 and 2007, Leece et al., 2017, established that the incidence was 5.57/100,000 for overall CNS tumors, and an average of 2.98/100,000 for astrocytic tumors, which preferentially affected patients over 45 years of age.
-
As per Crocetti et al., incidence rates for astrocytic tumors vary widely across European regions ranging from 3/100,000 in Eastern Europe to 5/100,000 in the United Kingdom and Ireland. Overall, an annual incidence rate of 4.8 per 100,000 for astrocytic cancers was estimated every year in Europe.
Key benefits of the report:
-
Astrocytoma market report covers a descriptive overview and comprehensive insight of the Astrocytoma Epidemiology and Astrocytoma market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
-
The Astrocytoma market report provides insights into the current and emerging therapies.
-
Astrocytoma market report provides a global historical and forecasted market covering drug outreach in 7MM.
-
The Astrocytoma market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Astrocytoma market.
Astrocytoma Overview
The brain is made up of various types of cells, including neurons, which constitute the electric circuitry responsible for brain functions, and astrocytes, which provide the structure and support for neurons to work properly. Astrocytoma is a type of cancer that can form in the brain or spinal cord. It begins in cells called astrocytes that support nerve cells, and are the most common brain tumors in adult individuals.
Astrocytoma Market
The dynamics of the Astrocytoma market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as Denovo Biopharma, Orbus Therapeutics, Diffusion Pharmaceuticals, Tactical Therapeutics, Oncoceutics, and others during the forecasted period 2018-2030.
Astrocytoma Pipeline Therapies and Key Companies
-
DB102 (Enzastaurin): Denovo Biopharma
-
Eflornithine: Orbus Therapeutics
-
Trans Sodium Crocetinate (TSC): Diffusion Pharmaceuticals
-
Pravitinib (Carboxyamido Triazole Orotate): Tactical Therapeutics
-
ONC201: Oncoceutics
Astrocytoma Market Drivers
-
Robust Pipeline Activity in the 7MM
-
Improvement in technological advancements consumer education and awareness on Astrocytoma
Table of Contents
1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Astrocytoma Patient Share (%) Overview at a Glance
5. Astrocytoma Market Overview at a Glance
6. Astrocytoma Disease Background and Overview
7. Astrocytoma Epidemiology and Patient Population
8. Country-Specific Patient Population of Astrocytoma
9. Astrocytoma Current Treatment and Medical Practices
10. Unmet Needs
11. Astrocytoma Emerging Therapies
12. Astrocytoma Market Outlook
13. Country-Wise Astrocytoma Market Analysis (2018–2030)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Astrocytoma Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Related Reports:
“Astrocytoma Pipeline Insight, 2021” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Astrocytoma market. A detailed picture of the Astrocytoma pipeline landscape is provided, which includes the disease overview and Astrocytoma treatment guidelines.
DelveInsight’s ‘Astrocytoma Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Astrocytoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/